17-Dimethylaminoethylamino-17-demethoxygeldanamycin
Names | |
---|---|
IUPAC name
[(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-21-(2-dimethylaminoethylamino)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate | |
Other names
17-DMAG; Alvespimycin | |
Identifiers | |
467214-20-6 | |
ChEBI | CHEBI:65324 |
ChEMBL | ChEMBL383824 |
ChemSpider | 16744073 |
Jmol interactive 3D | Image Image |
PubChem | 5288674 |
| |
| |
Properties | |
C32H48N4O8 | |
Molar mass | 616.76 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) is a chemical compound which is a semi-synthetic derivative of the antibiotic geldanamycin.[1][2] It is being studied for the possibility of treating cancer.[3]
References
- ↑ WO application 2002079167, Snader, Kenneth M.; Vishnuvajjala, B. Rao; Hollingshead, Melinda G.; Sausville, Edward A., "Preparation of geldanamycin derivatives for the treatment of cancer", published 2002
- ↑ Rastelli, Giulio; Tian, Zong-Qiang; Wang, Zhan; Myles, David; Liu, Yaoquan (2005). "Structure-based design of 7-carbamate analogs of geldanamycin". Bioorganic & Medicinal Chemistry Letters 15 (22): 5016–5021. doi:10.1016/j.bmcl.2005.08.013.
- ↑ Sausville, E. A.; Tomaszewski, J. E.; Ivy, P. (2003). "Clinical development of 17-allylamino, 17-demethoxygeldanamycin". Curr. Cancer Drug Targets 3 (5): 377–83. doi:10.2174/1568009033481831. PMID 14529389.
This article is issued from Wikipedia - version of the Tuesday, December 08, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.